| Erin Renae Stevens, MD | |
|
6545 France Ave S, Edina, MN 55435-2131 | |
| (952) 922-7600 | |
| Not Available |
| Full Name | Erin Renae Stevens |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 11 Years |
| Location | 6545 France Ave S, Edina, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174966808 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 61800 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinic Sofia Obgyn Pa | 2466404991 | 9 |
News Archive
Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."
In a SciDev.Net editorial, David Dickson, director of SciDev.Net, examines progress towards the Millennium Development Goal (MDG) targets, highlighting their usefulness as well as their shortcomings. "The value of the MDGs lies in the way they have acted as both a carrot and a stick to focus the efforts of both development agencies and governments of developing countries," according to Dickson, who writes that "the curse of the MDGs is that they focus on relatively short-term, concrete objectives, and lack sufficient 'buy-in' from the very countries they are intended to help.
Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
Scientists from the University of Granada have developed a new fluorescent dye capable of detecting, in a single test lasting 20 minutes, the presence of phosphate and biothiol inside living cells. This scientific breakthrough could contribute significantly to the early diagnosis of diseases such as osteoporosis, Alzheimer's, type 2 diabetes, and prostate cancer, since abnormal levels of both substances are associated with these diseases.
› Verified 8 days ago
| Entity Name | Clinic Sofia Obgyn Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245218825 PECOS PAC ID: 2466404991 Enrollment ID: O20050214000191 |
News Archive
Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."
In a SciDev.Net editorial, David Dickson, director of SciDev.Net, examines progress towards the Millennium Development Goal (MDG) targets, highlighting their usefulness as well as their shortcomings. "The value of the MDGs lies in the way they have acted as both a carrot and a stick to focus the efforts of both development agencies and governments of developing countries," according to Dickson, who writes that "the curse of the MDGs is that they focus on relatively short-term, concrete objectives, and lack sufficient 'buy-in' from the very countries they are intended to help.
Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
Scientists from the University of Granada have developed a new fluorescent dye capable of detecting, in a single test lasting 20 minutes, the presence of phosphate and biothiol inside living cells. This scientific breakthrough could contribute significantly to the early diagnosis of diseases such as osteoporosis, Alzheimer's, type 2 diabetes, and prostate cancer, since abnormal levels of both substances are associated with these diseases.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Renae Stevens, MD 6545 France Ave S, Edina, MN 55435-2131 Ph: () - | Erin Renae Stevens, MD 6545 France Ave S, Edina, MN 55435-2131 Ph: (952) 922-7600 |
News Archive
Omni Eye Services, a leading provider of ophthalmologic services at five locations in New York and New Jersey, today announced that Dr. Katherine M Mastrota, Center Director of Omni Eye Surgery in New York City, has written a treatment update for Contact Lenses Today describing a promising "new option for managing lid disease."
In a SciDev.Net editorial, David Dickson, director of SciDev.Net, examines progress towards the Millennium Development Goal (MDG) targets, highlighting their usefulness as well as their shortcomings. "The value of the MDGs lies in the way they have acted as both a carrot and a stick to focus the efforts of both development agencies and governments of developing countries," according to Dickson, who writes that "the curse of the MDGs is that they focus on relatively short-term, concrete objectives, and lack sufficient 'buy-in' from the very countries they are intended to help.
Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.
Scientists from the University of Granada have developed a new fluorescent dye capable of detecting, in a single test lasting 20 minutes, the presence of phosphate and biothiol inside living cells. This scientific breakthrough could contribute significantly to the early diagnosis of diseases such as osteoporosis, Alzheimer's, type 2 diabetes, and prostate cancer, since abnormal levels of both substances are associated with these diseases.
› Verified 8 days ago
Dr. April Batcheller, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6565 France Ave S Ste 400, Edina, MN 55435 Phone: 952-225-1630 | |
Dr. Anne M Meschke, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3625 W 65th St, Suite 100, Edina, MN 55435 Phone: 952-920-7001 Fax: 952-920-2245 | |
Rachel Amanda Harris, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3625 W 65th St Ste 100, Edina, MN 55435 Phone: 952-345-7070 Fax: 952-345-0472 | |
Mackenzie Thayer, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 6405 France Ave S Ste W400, Edina, MN 55435 Phone: 952-920-2730 | |
Kimberly Anne Gerten, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6565 France Ave S Ste 200, Edina, MN 55435 Phone: 952-920-2200 Fax: 952-920-0866 | |
Suzin Cho, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6565 France Ave S, Suite 200, Edina, MN 55435 Phone: 952-920-2200 Fax: 952-920-0866 | |
Annelise S Swigert, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3625 W 65th St, Suite 100, Edina, MN 55435 Phone: 952-920-7001 Fax: 952-920-2245 |